40 results
8-K
EX-99.1
IMUX
Immunic Inc
20 Oct 20
EIB Provides Immunic With up to €24.5 Million to Support Ongoing Development of a Potential COVID-19 Therapy
7:19am
to accelerate the development of innovative treatments against coronavirus and other severe diseases faced by our society.”
“The funding commitment … to innovative players active in developing vaccines, drugs, medical and diagnostic devices and research infrastructure for combating infectious diseases
424B5
IMUX
Immunic Inc
11 Jun 20
Prospectus supplement for primary offering
4:10pm
of IMU-935 is currently ongoing.
Our third program, IMU-856, which we believe to be novel and highly innovative, is an orally available, small molecule
424B5
IMUX
Immunic Inc
9 Jun 20
Prospectus supplement for primary offering
9:56pm
is currently ongoing.
Our third program, IMU-856, which we believe to be novel and highly innovative, is an orally available, small molecule modulator
424B5
yelng
27 Apr 20
Prospectus supplement for primary offering
12:00am
8-K
yuu99d p0dz1xqrol72
17 Jul 19
Updated Unaudited Pro Forma Condensed Combined Financial Information
5:15pm
8-K
EX-10.3
uwbgh
17 Jul 19
Updated Unaudited Pro Forma Condensed Combined Financial Information
5:15pm
8-K
EX-99.1
yoj6n mij0
15 Apr 19
Immunic Therapeutics and Vital Therapies Complete Transaction
4:30pm
424B3
v5ix4pt8nw
19 Feb 19
Prospectus supplement
5:03pm
S-4/A
1ccwxd qf
14 Feb 19
Registration of securities issued in business combination transactions (amended)
9:02am
S-4
oa456r3 2tf258
4 Feb 19
Registration of securities issued in business combination transactions
5:58pm